Rigel Pharmaceuticals said updated Phase 1b data for R289 in lower-risk myelodysplastic syndrome will be presented in an oral session at the ASH Annual Meeting.

Rigel Pharmaceuticals said updated Phase 1b data for R289 in lower-risk myelodysplastic syndrome will be presented in an oral session at the ASH Annual Meeting. The company disclosed no findings, but the slot highlights continued hematology pipeline activity.